Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction

Short Title
MAT-PDOA
Modified Announcement

Please note that the word “hospital” was removed from pages 5 and 34 of the RFA. The modified language now says “Priority will be given to states that have not only demonstrated a high rate of primary treatment admissions for heroin and opioids per capita, but that have also demonstrated a dramatic increase in admissions in recent years.” 

Notice of Funding Opportunity (NOFO)
NOFO Number
TI-15-007
Posted on Grants.gov
Application Due Date
Catalog of Federal Domestic Assistance (CFDA) Number
93.243
Intergovernmental Review (E.O. 12372)
Applicants must comply with E.O. 12372 if their state(s) participates. Review process recommendations from the State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.
Public Health System Impact Statement (PHSIS) / Single State Agency Coordination
Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.
Description

The purpose of this program is to provide funding to states to enhance/expand their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based medication assisted treatment (MAT) and recovery support services to individuals with opioid use disorders seeking or receiving MAT.  As a result of this program, SAMHSA seeks to: 1) increase the number of individuals receiving MAT services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders; 2) increase the number of individuals receiving integrated care; and 3) decrease illicit drug use at 6-months follow-up. 

For the purpose of this RFA, integrated care is defined as the organized delivery and/or coordination of medical, behavioral or social and recovery support services provided to individual patients in order to produce better overall health outcomes for people that may have multiple healthcare needs.  MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products including extended-release and oral formulations) to prevent relapse to opioid use.  MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT) and case management.  MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies and when needed pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered and individualized setting.

Priority will be given to states (listed in Appendix V) that have not only demonstrated a high rate of primary treatment admissions for heroin and opioids per capita, but that have also demonstrated a dramatic increase in admissions in recent years. These states must include a statement confirming that their state has a rate of change for primary treatment admission for heroin and non-heroin opiates between the years 2007-2012 equal to or greater than 50 percent.  In order to receive priority, this documentation must be included in Attachment 5.

This program addresses SAMHSA’s Strategic Initiative on Prevention of Substance Abuse and Mental Illness.  

Eligibility

Eligibility is limited to 39 states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita, as identified by SAMHSA’s Treatment Episode Data Set (TEDS): 2002 - 2012, (see Appendix IV in the RFA for a list of eligible states).  The application must be submitted by the Single State Agency (SSA) for Substance Abuse within the state.

Eligibility has been limited to these states because SAMHSA strongly believes that these 39 states represent the highest rates of primary treatment admissions with heroin and opiates per capita.  In addition, SAMHSA has identified 18 of these states that have demonstrated a dramatic increase in admissions for the treatment of opiates and heroin in recent years and will be given priority for funding.  This approach is consistent with the language used to describe the program in the Committee Report accompanying the FY 2015 Consolidated Appropriations Bill.  

Award Information
Funding Mechanism
Grant
Anticipated Total Available Funding
$11,000,000
Anticipated Number of Awards
Up to 11
Anticipated Award Amount
Up to $1,000,000
Length of Project
Up to 3 years
Cost Sharing/Match Required?
No

Proposed budgets cannot exceed $1,000,000 in total costs (direct and indirect) in any year of the proposed project.  Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.

Contact Information
Program Issues

Anthony Campbell, RPH, D.O.
Medical Officer
Division of Pharmacologic Therapy, Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Room 2-1067
Rockville, Maryland 20857
(240) 276-2702
tony.campbell@samhsa.hhs.gov

Grants Management and Budget Issues

Eileen Bermudez
Office of Financial Resources, Division of Grants Management
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Room 7-1091
Rockville, Maryland 20857
(240) 276-1412
eileen.bermudez@samhsa.hhs.gov

Last Updated: 04/29/2020

Have a question about government service? Contact USA.gov.